CVS Pharmacy Inc. and several of its subsidiaries have agreed to pay $315 million to settle a Department of Justice lawsuit alleging the company unlawfully dispensed medically unnecessary opioid prescriptions. The settlement, announced Tuesday, resolves a 2024 legal case that accused CVS of distributing large quantities of opioids and other controlled substances to boost profits at the expense of public health and safety.

The lawsuit, filed during the Biden administration, alleged CVS violated the Controlled Substances Act by filling illegitimate prescriptions for potent opioids, often prescribed by so-called "pill mills"—providers suspected of issuing prescriptions without legitimate medical purposes. According to the complaint, these actions contributed to wider issues of opioid dependence and addiction. The Justice Department also pointed to poor staffing levels, performance metrics, and incentive-based compensation as factors pressuring pharmacists to fill prescriptions quickly without adequate verification.

Assistant Attorney General Brett Shumate, who oversees the DOJ’s Civil Division, said CVS is required to put in place additional safeguards to ensure that opioids and other controlled substances are dispensed only when medically appropriate. Stanley Woodward, Associate Attorney General, described the settlement as a significant step in the government's ongoing efforts to hold pharmacies accountable and combat the opioid crisis.

CVS, based in Woonsocket, Rhode Island, issued a statement emphasizing that its pharmacists receive training on the safe and appropriate use of medications and that the company has implemented programs aimed at supporting responsible decision-making. While CVS expressed strong disagreement with the allegations, the company noted that the settlement does not constitute an admission of wrongdoing. The company has previously criticized the varying standards pharmacists face around opioid prescription fulfillment, describing them as vague and evolving.

The settlement is part of a broader government push to address the opioid epidemic, which has been linked to more than 100,000 overdose deaths annually at its peak. Over the past decade, drug manufacturers, wholesalers, pharmacies, and other entities have collectively agreed to pay over $50 billion in settlements to address various aspects of the crisis. Much of this funding is allocated toward prevention, treatment, and recovery efforts. Recent data indicate a decline in opioid overdose deaths, though the crisis continues to pose significant public health challenges.